Pharmacological Mechanisms in Alzheimer's Therapeutics PDF Download

Author: A. Claudio Cuello
Publisher: Springer Science & Business Media
ISBN: 0387715223
Category : Medical
Languages : en
Pages : 337

View

Book Description
The need for effective therapy to treat Alzheimer’s disease is greater than ever, but there is still no drug therapy that can stop or reverse the progression of the disease. There is, however, a great deal of anticipation over the imminent development of effective therapies as a result of the identification of promising targets for drug development. This book investigates these targets and examines ongoing strategies to develop effective therapies for this devastating neurodegenerative condition.

Author: Cesare Mancuso
Publisher: Frontiers Media SA
ISBN: 2889636313
Category :
Languages : en
Pages : 221

View

Book Description

Author: Jeffrey Cummings
Publisher: Cambridge University Press
ISBN: 1108985157
Category : Medical
Languages : en
Pages : 575

View

Book Description
Alzheimer's Disease (AD) is a growing global public health challenge. The development of new therapies is urgently needed, and a complex ecosystem of organizations has grown to facilitate AD drug discovery and development. Masterfully collating information on the drug development ecosystem, this book emphasizes the contributions of each aspect in the pipeline with a uniform approach to chapters, enabling readers to access relevant information quickly. Topics covered include the use of non-clinical laboratory studies, biomarker development, artificial intelligence, design and management of clinical trials, and funding and financing models. Also discussed is the critical role of advocacy fundraising for drug development. With the approval of aducanumab, the function of the ecosystem has become apparent. This is a definitive overview of how the ecosystem works in transferring an AD drug from its discovery in the laboratory through clinical trial testing to regulatory review and eventual marketing.

Author: Atta-ur Rahman
Publisher: Elsevier
ISBN: 0128039604
Category : Medical
Languages : en
Pages : 785

View

Book Description
Drug Design and Discovery in Alzheimer’s Disease includes expert reviews of recent developments in Alzheimer's disease (AD) and neurodegenerative disease research. Originally published by Bentham as Frontiers in Drug Design and Discovery, Volume 6and now distributed by Elsevier, this compilation of the sixteen articles, written by leading global researchers, focuses on key developments in the understanding of the disease at molecular levels, identification and validation of molecular targets, as well as innovative approaches towards drug discovery, development, and delivery. Beginning with an overview of AD pharmacotherapy and existing blockbuster drugs, the reviews cover the potential of both natural and synthetic small molecules; the role of cholinesterases in the on-set and progression of AD and their inhibition; the role of beta-site APP clearing enzyme-1 (BACE-1) in the production of ß-amyloid proteins, one of the key reasons of the progression of AD; and other targets identified for AD drug discovery. Edited and written by leading experts in Alzheimer’s disease (AD) and other neurodegenerative disease drug development Describes existing drugs for AD and current molecular understanding of the condition Reviews recent advances in the field, including coverage of cholinesterases, BACE-1, and other drug development targets

Author: Thimmaiah Govindaraju
Publisher: Royal Society of Chemistry
ISBN: 1839162309
Category : Medical
Languages : en
Pages : 695

View

Book Description
Handbook on Alzheimer's disease from aetiology and neurochemistry to diagnostic and therapeutic approaches. Intended to provide an introduction to all aspects of the disease.

Author: Gustavo Alves Andrade dos Santos
Publisher: Springer Nature
ISBN: 3030943836
Category : Medical
Languages : en
Pages : 239

View

Book Description
Alzheimer’s disease is the most prevalent form of dementia. Although it was discovered about a century ago, the first drugs applied in treatment were only introduced in therapy in the last 30 years. This book focuses on the clinical pharmacology of drugs that aim to delay the progression of Alzheimer’s disease, such as anticholinesterases and glutamate receptor antagonists, as well as treatment for the behavioral changes caused by the progression of the disease: antidepressants, antipsychotics, anxiolytics, and mood stabilizers. In addition, it describes important information about the pathophysiology and diagnostic methods of Alzheimer’s disease, emergency situations conditioned by the dementia process, and presents new perspectives for the treatment of Alzheimer’s disease. The ten chapters cover topics such as mechanism of action, dosage regimen, adverse reactions, drug interactions, toxicity profiles, among other information of clinical relevance. The work comprises evidence-based studies, providing a valuable resource for analyzing, prescribing and monitoring patients being treated for Alzheimer’s disease. Written by experts with solid professional experience, this book will appeal to pharmacologists, geriatricians, neurologists, psychiatrists, biomedical clinicians, and other healthcare professionals.

Author: Illana Gozes
Publisher: Academic Press
ISBN: 0128037121
Category : Psychology
Languages : en
Pages : 344

View

Book Description
Neuroprotection in Alzheimer’s Disease offers a translational point-of-view from both basic and clinical standpoints, putting it on the cusp for further clinical development with its emphasis on nerve cell protection, including the accumulation of knowledge from failed clinical trials and new advances in disease management. This book brings together the latest findings, both basic, and clinical, under the same cover, making it easy for the reader to obtain a complete overview of the state-of-the-field and beyond. Alzheimer's disease is the most common form of dementia, accounting for 60 to 80 percent of dementia cases. It is a progressive brain disease that slowly destroys memory, thinking skills, and eventually, even the ability to carry out the simplest tasks. It is characterized by death of synapses coupled to death nerve cells and brain degeneration which is manifested by loss of cognitive abilities. Understanding neuroprotection in Alzheimer’s disease will pave the path to better disease management and novel therapeutics. Comprehensive reference detailing neuroprotection in Alzheimer’s Disease, with details on nerve cell protection and new advances in disease management Combines the knowledge and points-of-view of both medical doctors and basic scientists, putting the subject at the forefront for further clinical development Edited by one of the leading researchers in Alzheimer’s Disease

Author: Helmut Kewitz
Publisher: W. Zuckschwerdt
ISBN:
Category : Medical
Languages : en
Pages : 336

View

Book Description

Author: Atta-ur-Rahman
Publisher: Bentham Science Publishers
ISBN: 9811401896
Category : Science
Languages : en
Pages : 282

View

Book Description
Frontiers in Clinical Drug Research - Alzheimer Disorders is a book series concerned with Alzheimer's disease (AD), a disease that causes dementia, or loss of brain function. This disease affects parts of the brain that affect memory, thought and language. Chapters in each volume focus on drug research with special emphasis on clinical trials, research on drugs in advanced stages of development and cure for Alzheimer’s disease and related disorders. Frontiers in Clinical Drug Research - Alzheimer Disorders will be of particular interest to readers interested in drug therapy of this specific neurodegenerative condition and related brain disorders as the series provides relevant reviews written by experts in the field of Alzheimer’s disease research. The eighth volume of this series features chapters covering critical discussions on new therapies for AD. The reviews in this volume include: - Novel Molecular Targets of Tauopathy; Therapeutic and Diagnostic Applications - The Therapy of Alzheimer’s Disease: Towards a New Generation of Drugs - Could Antibiotics Be Therapeutic Agents in Alzheimer’s Disease? - Use of Antipsychotics in Patients with Alzheimer’s Disease - Approaches Based on Cholinergic Hypothesis and Cholinesterase Inhibitors in the Treatment of Alzheimer's Disease - Potential Biological Mechanisms with Prophylactic Action in Rapid Cognitive Impairment in Late-Onset Alzheimer's Disease

Author: Ghulam Md Ashraf
Publisher: Springer Nature
ISBN: 9811396361
Category : Medical
Languages : en
Pages : 293

View

Book Description
This book discusses the latest research into the highly prevalent neurodevelopmental disease most commonly associated with aging: Alzheimer’s disease (AD). Even after years of research, Alzheimer’s disease is still far from being cured. It presents a range of common symptoms in the form of behavioral and cognitive impairments. This book describes the symptoms and the biology behind them. The contents covers latest findings on the genetics involved and various factors and pathways influencing disease development. It also covers various non-pharmacological therapies like immunotherapy, use of natural products, and employing nanotechnology in both the detection and treatment of AD. This book also highlights the role of diet and nutrition in healthy aging. Given its scope, it offers a valuable asset for researchers and clinicians alike.